We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Transport Pharmaceuticals has closed a $27 million Series D financing round to fund clinical development and commercialization of its therapy for herpes labialis, or cold sores.
On a Nov. 15 conference call to the financial community, ArthroCare announced the completed acquisition of San Juan Capistrano, Calif.-based Opus Medical, saying that it can now “move forward aggressively” with the deal.
In a move to expand its line of stent products, Boston Scientific has made an equity investment in and secured an exclusive option to purchase San Diego-based REVA Medical.
In a move to expand its presence in the vascular closure market, Medtronic has acquired privately held device firm Angiolink, which develops innovative wound closure solutions for vascular procedures.
Brand firm Otsuka America Pharmaceutical has signed an agreement allowing specialty pharma company Prasco Laboratories to launch an authorized generic version of its leg-pain drug Pletal — a launch that precedes outside generic competition on the product.
The pending acquisition of brand firm King Pharmaceuticals by generic heavyweight Mylan Laboratories is drawing fire from Mylan’s two largest shareholders, as well as industry analysts.
Overall reported political giving by the pharmaceutical and health products industries is down by more than one-half in the 2004 election compared with the last two election cycles — a trend that reflects new campaign finance laws and, perhaps, a lull in the battle after winning a hard-fought Medicare drug benefit.
Schering-Plough has agreed to pay Utah $1.8 million to settle allegations that the company overcharged the state’s Medicaid program for the antihistamine Claritin.
Generic heavyweight Mylan Laboratories’ pending acquisition of brand firm King Pharmaceuticals is drawing fire from Mylan’s two largest shareholders, as well as industry analysts.
Concerned about conflicts of interest in the business practices of pharmaceutical benefit managers (PBMs), a bipartisan group of senators wants the FTC to expand a study by examining deals with drugmakers and the extent to which PBMs pass on financial incentives through the distribution channel.